Neurocrine(NBIX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance ® INGREZZA (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32$2.25 - $2.3 Billion ® Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, August 1, 2024 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial resul ...